Black Rock Inc. Aveo Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$8.48 - $14.97 $1.54 Million - $2.72 Million	182,024 Added 35.23%	698,770 $10.4 Million
Q3 2022 Nov 14, 2022	SELL	$6.61 - $8.72 $49,330 - $65,077	-7,463 Reduced 1.42%	516,746 $4.25 Million
Q2 2022 Aug 12, 2022	SELL	$3.51 - $6.67 $449 - $853	-128 Reduced 0.02%	524,209 $3.44 Million
Q1 2022 May 12, 2022	SELL	$3.15 - $6.01 $10,990 - $20,968	-3,489 Reduced 0.66%	524,337 $2.93 Million
Q4 2021 Feb 10, 2022	SELL	$4.69 - $7.4 $22,413 - $35,364	-4,779 Reduced 0.9%	527,826 $2.48 Million
Q3 2021 Nov 09, 2021	BUY	$5.12 - $6.89 $275,522 - $370,771	53,813 Added 11.24%	532,605 $3.29 Million
Q2 2021 Aug 11, 2021	BUY	$6.21 - $7.45 $2.97 Million - $3.57 Million	478,792 New	478,792 $3.15 Million

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.